2021
Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry)
Daimee UA, Aslam F, Parzynski CS, Desai NR, Curtis JP. Longitudinal Outcomes Associated With Non-Evidence-Based Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries (From the National Cardiovascular Data Registry). The American Journal Of Cardiology 2021, 155: 64-71. PMID: 34315569, DOI: 10.1016/j.amjcard.2021.06.020.Peer-Reviewed Original ResearchConceptsPrimary prevention ICD implantationRisk of mortalityICD implantationHeart failureICD RegistryMortality riskNational Cardiovascular Data Registry ICD RegistryPivotal randomized clinical trialsHospital adverse eventsSevere heart failureRecent myocardial infarctionCause hospital readmissionRandomized clinical trialsSimilar mortality riskLongitudinal outcomesImplantable cardioverter defibrillatorGreater mortality riskCause hospitalizationCause mortalityCoronary revascularizationAdverse eventsHospital readmissionICD recipientsDevice implantationPrimary prevention
2014
In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention
Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, Roe MT, Bhatt DL, McNamara RL, Alexander KP. In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2014, 7: 585-593. PMID: 25097196, DOI: 10.1161/circinterventions.114.001555.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedClopidogrelDrug SubstitutionFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPiperazinesPostoperative ComplicationsPractice Guidelines as TopicPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsRecurrenceRegistriesRisk FactorsThiophenesThrombosisTiclopidineUnited StatesConceptsPercutaneous coronary interventionMyocardial infarctionCoronary interventionHospital coronary artery bypassIntervention Outcomes Network RegistryStudy periodAcute Coronary TreatmentHierarchical logistic regression modelingCoronary artery bypassRecurrent ischemic eventsHours of admissionPrevious cerebrovascular eventsRandomized clinical trialsAcute myocardial infarctionADP receptor inhibitorsLogistic regression modelingPrivate health insurance coverageHealth insurance coverageHospital bleedingHospital switchingAngiographic characteristicsArtery bypassCerebrovascular eventsContemporary US practiceCoronary Treatment
2013
Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials
Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials. JAMA 2013, 309: 55-62. PMID: 23280225, PMCID: PMC3638257, DOI: 10.1001/jama.2012.157182.Peer-Reviewed Original ResearchConceptsPrimary prevention ICDsPrimary prevention clinical trialsTrial-eligible patientsSurvival of patientsPrevention clinical trialsClinical trialsICD RegistrySCD-HeFTClinical practiceRegistry patientsMADIT-IISimilar patientsNational Cardiovascular Data Registry ICD RegistryPrimary prevention implantable cardioverter defibrillatorsSurvival rateImplantable cardioverter-defibrillator therapyMADIT II criteriaMADIT II patientsSCD-HeFT criteriaCardioverter-defibrillator therapyClinical trial patientsLarge national registryRandomized clinical trialsProportional hazards modelImplantable cardioverter defibrillator